Copyright
©The Author(s) 2016.
World J Hepatol. Nov 18, 2016; 8(32): 1402-1413
Published online Nov 18, 2016. doi: 10.4254/wjh.v8.i32.1402
Published online Nov 18, 2016. doi: 10.4254/wjh.v8.i32.1402
Table 1 Demographic and baseline characteristics, randomised population
| Patients characteristics | Telbivudine (n = 121) | Tenofovir (n = 120) |
| Age, mean (SD), yr | 42.1 (11.5) | 43.3 (12.6) |
| Median (min-max) | 42.0 (19-70) | 44.0 (18-73) |
| Male gender, n (%) | 86 (71.1) | 82 (68.3) |
| Race, Caucasian, n (%) | 117 (96.7) | 118 (98.3) |
| Body mass index, mean (SD), kg/m2 | 25.8 (4.1) | 25.7 (4.0) |
| Median (min-max) | 25.6 (16.5-40.4) | 25.2 (18.4-39.8) |
| Genotype, n (%) | ||
| A | 6 (5.0) | 2 (1.7) |
| B | 1 (0.8) | 0 (0.0) |
| C | 0 (0.0) | 1 (0.8) |
| D | 104 (86.0) | 110 (91.7) |
| G | 1 (0.8) | 0 (0.0) |
| Other | 1 (0.8) | 0 (0.0) |
| Unknown | 8 (6.6) | 7 (5.8) |
| HBV DNA, mean (SD), log10 copies/mL | 6.2 (1.5) | 6.0 (1.4) |
| Median (min-max) | 6.1 (3.2-9.5) | 5.9 (2.5-9.9) |
| < 7 log10, n (%) | 85 (70.2) | 86 (71.7) |
| ≥ 7 log10, n (%) | 36 (29.8) | 34 (28.3) |
| Serum alanine aminotransferase, mean (SD), IU/L | 79.8 (84.1) | 78.2 (86.1) |
| Median (min-max) | 53.0 (13-494) | 49.0 (5-568) |
| Serum aspartate aminotransferase, mean (SD), IU/L | 54.0 (52.8) | 52.5 (47.1) |
| Median (min-max) | 35.0 (13-347) | 35.0 (13-322) |
| Creatine phosphokinase, mean (SD), IU/L | 118.6 (64.4) | 160.1 (299.3) |
| Median (min-max) | 104.0 (35-430) | 111.0 (36-2976) |
| eGFR1, mean (SD), (mL/min per 1.73 m2) | 97.4 (17.9) | 95.8 (16.4) |
| Median (min-max) | 96.6 (60.9-147.1) | 94.2 (60.5-138.4) |
- Citation: Krastev Z, Petrova D, Kotzev I, Celen MK, Mendelson M, Chandra R, Pandey P, Hamed K. Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study. World J Hepatol 2016; 8(32): 1402-1413
- URL: https://www.wjgnet.com/1948-5182/full/v8/i32/1402.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i32.1402